Retrotope eyes $100m raise for neurodegenerative disease platform

https://www.clinicaltrialsarena.com   27 Aug 2021 California-based Retrotope aims to expand its investor pool as it prepares to potentially go public in the coming years. 

Currently, Retrotope has ongoing trials for RT001 in three of the four most common orphan neurodegenerative diseases— amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP) and Friedreich’s ataxia (FA). The ALS and PSP trials are Phase II, while the FA trial is a Phase II/III potentially IND-enabling study, company president Anil Kumar said.